Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: Accuracy of clinical assessment using the French trial database

Chest

Volumn 128, Issue 3, 2005, Pages 1442-1447

  Milleron, Bernard ^a   Westeel, Virginie ^b   Quoix, Elisabeth ^c   Moro Sibilot, Denis ^d   Braun, Denis ^e   Lebeau, Bernard ^f   Depierre, Alain ^b  

^a HÔPITAL TENON   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e General Hospital   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

Complete response; Lung cancer; Non small cell lung cancer; Preoperative chemotherapy; Response to chemotherapy

Indexed keywords

CISPLATIN; IFOSFAMIDE; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC ACCURACY; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATHOLOGY; PREDICTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STANDARD;

EID: 24944569180     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1442     Document Type: Article

References (21)

1. Dajczman E, Hanley J, Lisbona A, et al. Comparison of response evaluation in small cell lung cancer using computerized tomography and chest radiography. Lung Cancer 1994; 11:51-60
2. Pujol JL, Demoly P, Daures JP, et al. Chest tumor response measurement during lung cancer chemotherapy: comparison between computed tomography and standard roentgenography. Am Rev Respir Dis 1992; 145:1149-1154
3. Herschorn S, Hanley J, Wolkove N, et al. Measurability of non-small-cell lung cancer on chest radiographs. J Clin Oncol 1986; 4:1184-1190
4. Quoix E, Wolkove N, Hanley J, et al. Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer. Cancer 1988; 62:489-493
5. Gwyther SJ, Aapro MS, Hatty SR, et al. Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer. Anticancer Drugs 1999; 10:693-698
6. Thiesse P, Ollivier L, Di Stefano-Loumeau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 1997; 15:3507-3514
7. Pisters KM, Kris MG, Gralla RJ, et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993; 11:1757-1762
8. Schaefer-Prokop C, Prokop M. New imaging techniques in the treatment guidelines for lung cancer. Eur Respir J Suppl 2002; 35:71s-83s
9. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247-253
10. Miller AA, Hargis JB, Lilenbaum RC, et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol 1994; 12:2743-2750
11. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21:1752-1759
12. Margaritora S, Cesario A, Galetta D, et al. Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur J Cardiothorac Surg 2001; 19:894-898
13. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70:1826-1831
14. Albain KCS, Rush VR, Turrisi AT, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CTRT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from Intergroup Trial 0139 (RTOG 93-09) [abstract]. Proc Am Soc Clin Oncol 2003; 22:2497
15. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-1363
16. Burcombe RJ, Makris A, Pittam M, et al. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002; 38:375-379
17. Rose PG, Faulhaber P, Miraldi F, et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001; 82:17-21
18. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002; 35:179-187
19. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003; 125: 938-944
20. Cerfolio R, Bryant A, Winokur T, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004; 78:1903-1909
21. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004; 77:254-259, discussion 259